Pharmacological treatment for cerebral ischemia and cerebral vasospasm following subarachnoid hemorrhage (SAH) cannot attain sufficiently high concentrations of the drugs in the cerebrospinal fluid (CSF) without precipitating systemic side effects. We recently developed a liposomal drug delivery system for intrathecal application that can maintain effective concentrations of cerebral vasodilator, fasudil, in the CSF. A single intrathecal injection of liposomal fasudil could maintain a therapeutic drug concentration in the CSF over a period time due to their sustained-release property, significantly decreasing infarct size in a rat model of acute ischemia and reducing vasoconstriction of the rat and dog basilar artery in a model of SAH. In this review, we are introducing our new less-invasive intrathecal drug delivery system that provides an alternative and safe method to deliver therapeutic agents.
INTRODUCTION
Stroke is the third leading cause of death in the developed countries and the leading cause of major adult disability. It was projected that, if the age-specific rates of stroke remain unchanged, the overall number of strokes will increase owing to the rising percentage of the population in older group. Among the stroke patients, 85-90% of the cases are ischemic stroke with a predominant cause of cerebral arterial thrombosis. 1) Over the last decade, significant progresses have been made in the development of thrombolytic therapies for acute ischemic stroke. However, thrombolytic therapies have increased risk of cerebral hemorrhage, which limits their applications for certain patients.
Cerebral arterial vasospasm with delayed ischemic neurological deficit occurs in one-third of patients with aneurysmal subarachnoid hemorrhage (SAH).
2) Despite considerable advances in perioperative management of these patients, including the use of calcium antagonists, cerebral vasospasm, which is the delayed narrowing of major arteries at the base of the brain, still remains a major cause of morbidity and mortality and an important cause of cerebral ischemia and stroke after SAH. [3] [4] [5] Clearly, there is a crucial need for the development of neuroprotective therapies to improve clinical outcome of more patients with acute ischemic stroke or SAH.
The intravenous or intraperipheral route of administration requires larger doses of drugs than the intrathecal route, which could lead to adverse effects, reducing the therapeutic efficacy of the drug. The intrathecal route can overcome the inability of intravenously or peripherally administered drugs to allow distribution of the drugs through the entire neuraxis without the step of penetrating the blood-brain barrier. However, the morbidity associated with long-term intrathecal drug infusion through indwelling catheters, which are required for continuous drug administration, has precluded the application of this procedure in the clinical setting. Implantation of the catheter can cause adverse reactions, such as chronic inflammation and dural fibrosis, or result in spinal compression or infection, as has been shown in rodents and dogs. 6) Another limitation is that a second intervention may be required to remove the catheter and pump. 7, 8) Furthermore, the distribution of the infusate in the subarachnoid space (SAS) is not localized, and the agents may be redistributed to the systemic and cranial circulation without reaching the intended target. In addition, assuming bolus administration by the intrathecal route was feasible, the therapeutic window for the free drug may be too short due to redistribution to the systemic and cranial circulation.
To overcome the problems described above, an alternative intrathecal delivery strategy has been reported by Aebischer et al. 9) In this technique, primary cells or cells that are genetically engineered to produce a specific signaling molecule, such as growth factor, are encapsulated in a polymeric membrane and implanted in the SAS. Although this strategy is promising, maintaining long-term cell function and viability of encapsulated cells is difficult to achieve. Furthermore, implantation of this drug delivery system (DDS) is highly invasive and the implant site may be distant from the intended target site. Other intrathecal DDSs have been introduced for the treatment of experimental vasospasm. Inoue et al. demonstrated that intrathecal implantation of a slow-release tablet containing calcitonin gene-related peptide prevented vasospasm after SAH in monkeys.
10) Kasuya and co-workers reported that a prolonged-release pellet of papaverine implanted intracranially during surgery prevented vasospasm in dogs 11, 12) and in human patient. 13, 14) Tamargo and co-workers also reported that the controlled release formulation (ethylene-vinyl acetate polymer) containing nitric oxide donor (diethylenetriamine/NO) or ibuprofen is effective in preventing delayed cerebral vasospasm in an SAH model in nonhuman primates. [15] [16] [17] [18] [19] [20] [21] All methods introduced here require intracranial implantation via a craniotomy because the drug is in solid form. In addition, a substantial question has been raised regarding the solid drug form. If sustained-release pellets, tablets or gels were effective only locally, then those placed during surgery would not eliminate vasospasm in other vascular distributions, which is a relatively common occurrence in severe SAH. To overcome these disadvantages, therefore, a novel intrathecal DDS that is less invasive and allow diffuse distribution of the drug through the entire neuraxis via the CSF would be desirable.
ADVANTAGES OF LIPOSOMES FOR INTRATHECAL APPLICATION
Liposomes are composed of naturally-occurring, biodegradable lipids organizes into bilayer lipid membranes enclosing an aqueous core. The main objectives of the use of liposomes as DDS are sustained drug release and a decrease in toxicity (to increase the therapeutic index of the drug). As described earlier, effective treatment of cerebral ischemia requires that concentrations of the drug in CSF be maintained within the therapeutic range. Under such circumstances, the advantages of using liposomes by intrathecal application are four-fold. First, liposomes cannot cross the blood brain barrier. This keeps the drug confined primarily to the central nervous system, preventing adverse systemic effects. Second, intrathecal application of liposomes directly into the CSF allows diffuse distribution of themselves through the CSF pathway due to their liquid form. Third, encapsulation of drug in liposomes changes the pharmacokinetics of the free drug and provides sustained release of the drug with a long half life in CSF. Fourth, although the morbidity associated with long-term intrathecal drug administration through indwelling catheters has precluded the practical application of these procedures in the clinical setting, the use of liposomeentrapped drug can avoid the problems related to continuous infusion. A sustained-release preparation of drug, small enough to be applied in the SAS at the time of lumber puncture, could continuously deliver drug into the SAS without the risk of infection associated with externalized catheters or intravenous routes and, therefore, might be used prophylactically.
CEREBRAL VASODILATOR, FASUDIL
Fasudil [1-(5-isoquinolinesulphonyl)-homopiperazune: HA1077] (Fig. 1) , a new type of cerebral vasodilator, is different from currently used so-called Ca 2ϩ antagonists/channel blockers, such as verapamil, nifedipine and diltiazem, in that the drug processes not only blocking action against Ca 2ϩ entry 22,23) but also inhibitory effects on variety of serine/threonine protein kinases, including myosin light chain kinase, [24] [25] [26] [27] [28] protein kinase C, 24, 28) and Rho-associated kinase. 28) Fasudil can reverse cerebral blood flow in the normal conscious rats 29) and dilate the spastic cerebral arteries in an experimental SAH model. 30) Furthermore, fasudil has been reported to effective in patients with SAH, 31) and was first permitted to be used in Japan as a remedy for ischemic insults due to chronic cerebral vasospasm. However, intrathecal usage of fasudil which is a free form has been the subject of some controversy because of previously noted toxicity.
PREPARATION OF FASUDIL-CONTAINING LIPOSOME
The intra-CSF administration of liposome-entrapped drugs has been used in chemotherapy for brain tumors in rats, 32) monkeys, 33) and humans. 34) In addition, liposomes composed of hydrogenated soy phosphatidylcholine (HSPC) and cholesterol (CHOL) were non-toxic. 35, 36) Therefore, we chose the liposome having the lipid composition (HSPC : CHOL (2 : 1 mol/mol)) to develop an intrathecal DDS for the SAS. [37] [38] [39] [40] [41] To meet pharmaceutical demands for clinical use, efficient drug loading method should be required. We therefore tested the remote (active) loading methods, in which drug molecules are loaded into preformed liposomes using potential differences across liposomal membrane such as a proton gradient. 42, 43) Lipophilic drugs are able to permeate bilayer membranes, orders of magnitude faster in the neutral (uncharged) form than in the charged form. An unprotonated amphipathic base crosses the liposomal membrane and is then protonated inside the liposomes (H ϩ rich). Thus, drug molecules could be concentrated and trapped within the liposomes during incubation at higher temperature than the phase transition temperature of lipid (Tc). For instance, doxorubicin or vincristine, a weak base, has been successful loaded into preformed liposomes via the use of a pH gradient 42) or an ammonium sulfate gradient. 43) Fasudil is also a weak base with a molecular weight, 336.84, smaller than doxorubicin or vincristine. Therefore, fasudil has been expected to be loaded into preformed liposomes by remoteloading technique.
As shown in Fig. 2 , the use of the remote-loading technique resulted in higher drug encapsulation efficiencies, compared with a passive liposome entrapment technique, in which the drug is included in the hydration buffer during liposome preparation. Although fasudil was accumulated into HSPC/Chol liposomes (100 nm in a diameter) in response to a proton gradient (DpH of 5.0), the loading efficiency was Liposomes were prepared in the presence of either 300 mM citric acid (pH 3.0) (᭹) or 250 mM ammonium sulfate (pH 3.0) (᭡). The prepared liposomes were incubated in the presence of fasudil at 65°C for the incubated periods after the external vesicle medium was exchanged with 10% (w/v) sucrose containing 25 mM Trizma base (pH 8.0). Fasudil, which was encapsulated in the preformed liposomes, was determined after removal non-encapsulated fasudil by passing over Sephadex G-50 column.
still low (27.8%) at 10 min (Fig. 2) . Another proton gradient (DpH of 5.0) in combination with ammonium sulfate (250 mM) could improve the encapsulation efficiency (83.5%) (Fig. 2 ). An increasing the ammonium sulfate concentration produced an increase in the efficiency of drug encapsulation (data not shown). These results demonstrate that the ammonium sulfate gradient, rather than the transmembrane proton gradient, is the major driving force for the uptake of fasudil. Interestingly, the loading processes were separated into a fast phase for drug uptake and then a slower phase for the efflux (Fig. 2) . The efflux of highly protonated fasudil, once it was loaded, cannot be explained by simple or passive diffusion or by an increase in membrane permeability. It is known that some highly ionized compounds such as quarternary ammonium compounds form electrochemical neutral complexes with either anions or cations. These neutral ion-pair complexes cross the lipid membrane by passive diffusion (ionpair transport). Protonated fasudil molecules, inside the liposomes, might form electrochemical neutral complexes with anions such as SO 4 2Ϫ and citric acid and the resulting complexes then begin to effuse by crossing the liposomal membrane at higher temperature than Tc of the membrane.
We followed the stability of fasudil-containing liposomes at 4°C with respect to retention of the encapsulated drug and changes in the size distribution. Nearly 100% of the encapsulated drug (Ͼ95%) was retained inside the liposomes after 180 d at low temperature (4°C). No change in size distribution was observed for periods during the storage. In addition, any chemical degradation of fasudil and lipids (HEPC and CHOL) was detected following storage for long periods. These results indicate that the fasudil-loaded liposomes can meet pharmaceutical demands for a safety trial in humans and clinical use.
SAFETY STUDY OF LIPOSOME-ENTRAPPED FASUDIL FOLLOWING INTRATHECAL ADMINISTRATION IN RATS
Free fasudil administered intrathecally induced considerable adverse effects. The rats receiving two highest doses (0.25 or 0.10 mg free fasudil) died. The rats receiving 0.05 mg free fasudil showed abnormal posturing. The rat which received 0.025 mg free fasudil had a mild seizure, but quickly recovered. The rat which received the lowest dose (0.01 mg) was somewhat restlessness, but there were no other obvious adverse effects.
To examine the safety of liposomal fasudil, a higher dose (5 mg/kg) was intrathecally administered to the rats. At a such higher dose (10-fold higher than those that began to produce serious adverse effects for the free drug), liposomal fasudil caused no significant changes in values for mean arterial blood pressure, heart rate, or arterial carbon dioxide pressure. Gross examination revealed that the brain, vessels and meninges of all rats appeared normal, and on light microscopy, the brain parenchyma, ependyma, vessels, and basal meninges seemed normal histologically. Light microscopy performed in a limited number of rat basilar arteries demonstrated the typical changes of vasospasm among rats treated with drug-free liposomes (i.e., marked vasoconstriction associated with a degree of endothelial corrugation).
DRUG RELEASE KINETICS FROM THE FASUDIL-LOADED LIPOSOMES IN VITRO
In human CSF at 37°C, the release of fasudil from liposomes in CSF was biphasic, with a T 1/2a of 2.5 h and a T 1/2b of 355 h (Fig. 3) . This relatively slow release of a drug from liposomes mimics some aspects of drug infusion into SAS, including a significant decrease in the toxicity of the free drug. Release of passively encapsulated carboxyfluorescein (CF), an aqueous phase marker and membrane impermeable dye, was much slower than loaded fasudil (Fig. 3) . This indicates that the release of fasudil from liposomes was caused by the diffusion of fasudil molecules through the lipid membranes, not by the disruption of liposomes, during their incubation in the CSF.
NEUROPROTECTIVE EFFECT IN A MODEL OF IS-CHEMIA
Focal cerebral ischemia in rats was induced by middle cerebral artery occlusion using an intraluminal suture technique. 44, 45) The infarct brain tissue in the left MCA territory was differentiated using 2,3,5-triphenyltetrazolium chloride staining method. 46) Treated rats received 0.25 mg liposomeentrapped fasudil via the cisterna magna 2 h after ischemia insult and control rats received drug-free liposomes. Neurological condition and the infarct size were assessed at 24 h and 72 h after ischemia. Treated animals showed significantly improved neurological outcomes after the 24-h observation period compared to the control group (Table 1) . The control group, which received drug-free liposomes, showed no adverse effect throughout the experiment. Treatment with 0.25 mg liposomal fasudil resulted in a reduction in the infarct area (24 h: 29.0Ϯ4.4%, 72 h: 28.1Ϯ3.9% of total brain slices) compared to controls (49.6Ϯ4.6%, pϽ0.001), but there was no statistical difference between 24 and 72 h (Fig.  4) .
It has been shown that intravenous administration of fa- Fasudil was loaded into the preformed liposomes by means of remote-loading with an ammonium sulfate gradient. CF was passively encapsulated into the liposomes. For the fasudil-loaded liposomes, aliquots were removed at specified time points and applied to a Sepharose CL-4B column to separate fasudil still associated with the liposomes from the leaked drug. The latency of fasudil in the liposomes was calculated by dividing the drug to phospholipid ratio at specified time point by the initial drug to phospholipids ratio. For the liposomes containing CF, aliquots were removed and determined the increase in fluorescence due to released CF. Cited from ref. 38. sudil in a microembolism model of rats prevents the accumulation of neutrophils, resulting in decrease of the infarct area and improvement of neurological functions. 47) Intrathecal application of liposomal fasudil directly into the CSF allowed diffuse distribution of the drug through the CSF pathways. If this is the case, liposomal fasudil small enough to be applied in the CSF may achieve a vasodilating effect and may be effective to prevent cerebral ischemia. In the study, the therapeutic effect up to 72 h after ischemia was determined. More prolonged observation might be needed to know the true protective effect of liposomal fasudil on ischemia.
PREVENTION OF VASOCONSTRICTION IN MODEL OF SAH
SAH in a rat 48, 49) or dog 50) was induced by injection of autologous arterial blood into the cisterna magna twice. The animals received two injections, 48 h apart, of autologous arterial blood into the cisterna magna and this successfully induced delayed vasoconstriction of basilar artery (Figs. 5, 6 ). In the rat model of SAH, treated group received 0.417 mg liposome-entrapped fasudil via the cisterna magna and control rats received drug-free liposomes in the same manner. The diameter of the basilar artery was assessed at 7 d after the initial blood injection. Liposomal fasudil significantly prevented vasoconstriction in the basilar artery when compared to that of the control group (87.7Ϯ6.1% vs. 66.3Ϯ 9.8%, respectively, pϽ0.001 (Fig. 5) ). In the canine SAH model, a single intrathecal dose of liposomal fasudil reduced the severity of cerebral vasospasm significantly on day 7 (Fig. 6) . Without liposomal fasudil treatment, the caliber of the dogs' basilar arteries on day 7 was 55.9Ϯ4.8% (placebo group) and 53.4Ϯ5.5% (control group) of the pre-SAH value. Treatment with liposomal fasudil (treatment group) resulted in milder vessel changes on day 7 (86.2Ϯ5.1%). In the canine SAH model, a caliber change improvement of approximately 30% was noted in the treatment group. Intrathecal administration of fasudil-loaded liposomes, a sustained-drug release system, could significantly reduce the severity of narrowing in basilar artery and produce no obvious adverse effect in the rat SAH model. This might be due that the intrathecal application enhances the vasodilating effect of fasudil because direct application into the CSF allows diffuse distribution of the drug, sustained-released from the liposomes, through the entire neuraxis. As liposomal fasudil small enough to be applied in the CSF could continuously deliver drug into the brain parenchyma, the use of them could be advantageous in comparison with peripheral administration.
DRUG RELEASE KINETICS FROM THE FASUDIL-LOADED LIPOSOMES IN VIVO
In the rat model of cerebral ischemia, the concentration of fasudil-entrapped liposomes in the CSF 24 h after ischemic insult was 45.4Ϯ31.5 mg/ml. Based on the administered dose of 0.25 mg fasudil/rat, and an average of 1.0 ml of CSF per 300 to 400 g rat, the initial concentration of liposomal fasudil would be 250 mg/ml. Thus, approximately 20% of injected fasudil was still remained at 24 h following focal cerebral ischemia. In the rat model of SAH, the concentration of liposomal fasudil in the CSF 7 d after SAH was 0.98Ϯ0.69 mg/ml. Less than 1% of injected dose was remained, since the initial concentration of liposomal fasudil was 417 mg/ml. In dog model of SAH, at 5 d after the liposome injection into CSF, 90% of injected liposomal fasudil was disappeared. The free fasudil released from the liposomes must be quickly eliminated from or distributed into SAS. Thus, the concentration of free drug must be below the detection limit with our assay. Thus, the concentration of fasudil detected in the CSF is thought to be the encapsulated form, not free form, in the CSF.
The drug release rate from liposomes would be dependent on various conditions, including the liposome composition and size, the physicochemical properties of the drug, and the method of drug loading into liposomes. 51) It has been widely accepted that interaction with blood components and the mononuclear phagocyte system are responsible for the clearance of liposomes following intravenous injection. 52) In the case of SAH, CSF contains a small amount of blood compared to blood stream. Therefore, it is conceivable that blood components in the CSF might not be accountable for accelerating the drug release from liposomes in vivo. However, as the clearance and elimination of liposomes in the CSF are little understood, further experiments will be required to clarify the optimal drug release rate as well as circulation of liposomes in the CSF.
CONCLUSION
We confirmed that liposome-entrapped fasudil can be safe and applied in the CSF in rats and dogs, but the circulation and kinetics of the drug in the SAS still remain to be understood. Further investigations must be employed to clarify the pharmacokinetics of the drug and liposome itself in the CSF. In addition, the drug release rate can be further manipulated by changing the liposome characteristics if a slower or faster release rate is deemed desirable to maintain an adequate therapeutic drug concentration in the CSF. Physicochemical characteristics of liposome such as lipid composition and size are well known to affect the release rate of the content from the liposomes. We therefore need to perform examination on selection of liposome type. These further investigations will be possible to envision clinical trials and clinical use of fasudil-loaded liposomes.
